Docking-Based Virtual Screening and Molecular Dynamics Simulations of Quercetin Analogs as Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors of Mycobacterium tuberculosis

被引:25
|
作者
Pitaloka, Dian Ayu Eka [1 ,2 ]
Ramadhan, Dwi Syah Fitra [3 ]
Arfan [4 ]
Chaidir, Lidya [2 ,5 ]
Fakih, Taufik Muhammad [6 ]
机构
[1] Univ Padjadjaran, Dept Pharmacol & Clin Pharm, Fac Pharm, Sumedang 45363, Indonesia
[2] Univ Padjadjaran, Ctr Translat Biomarker Res, Sumedang 45363, Indonesia
[3] STIKES Mandala Waluya Kendari, Dept Pharmaceut Chem, Kendari 93231, Indonesia
[4] Univ Halu Oleo, Fac Pharm, Dept Med Chem, Kendari 93132, Indonesia
[5] Univ Padjadjaran, Dept Biomed Sci, Fac Med, Sumedang 45363, Indonesia
[6] Univ Islam Bandung, Fac Math & Nat Sci, Dept Pharm, Bandung 40116, Indonesia
关键词
virtual screening; dynamic simulation; isoniazid; quercetin; multidrug-resistant tuberculosis;
D O I
10.3390/scipharm89020020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The emergence of multidrug-resistant Mycobacterium tuberculosis (MTB) has become a major problem in treating tuberculosis (TB) and shows the need to develop new and efficient drugs for better TB control. This study aimed to use in silico techniques to discover potential inhibitors to the Enoyl-[acyl-carrier-protein] reductase (InhA), which controls mycobacterial cell wall construction. Initially, 391 quercetin analogs present in the KNApSAck_3D database were selected, filters were sequentially applied by docking-based virtual screening. After recategorizing the variables (bond energy prediction and molecular interaction, including hydrogen bond and hydrophobic bond), compounds C00013874, C00006532, and C00013887 were selected as hit ligands. These compounds showed great hydrophobic contributions, and for each hit ligand, 100 ns of molecular dynamic simulations were performed, and the binding free energy was calculated. C00013874 demonstrated the greatest capacity for the InhA enzyme inhibition with Delta Gbind = -148.651 kcal/mol compare to NAD (native ligand) presented a Delta Gbind = -87.570 kcal/mol. These data are preliminary studies and might be a suitable candidate for further experimental analysis.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Synthesis of hydrophobic N-acylated isonicotinic acid hydrazide derivatives as potential enoyl-acyl carrier protein reductase (InhA) inhibitors
    Kumar, H. S. Naveen
    Parumasivam, Thaigarajan
    Ibrahim, Pazilah
    Asmawi, Mohd Zaini
    Sadikun, Amirin
    MEDICINAL CHEMISTRY RESEARCH, 2014, 23 (03) : 1267 - 1277
  • [32] Structure-Based Design of a Novel Class of Potent Inhibitors of InhA, the Enoyl Acyl Carrier Protein Reductase from Mycobacterium Tuberculosis: A Computer Modelling Approach
    Rao, Gita Subba
    Vijayakrishnan, Rajakrishnan
    Kumar, Manoj
    CHEMICAL BIOLOGY & DRUG DESIGN, 2008, 72 (05) : 444 - 449
  • [33] Effects of Enoyl-Acyl Protein Carrier Reductase Mutations on Physiochemical Interactions with Isoniazid: Molecular Dynamics Simulation
    Choong, Yee Siew
    Wahab, Habibah A.
    INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE, 2011, 6 (09): : 4032 - 4047
  • [34] Drug repurposing approach against Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase: insight from molecular dynamics simulations
    Kisten, Kimona
    Kumalo, Hezekiel M.
    Machaba, Kgothatso E.
    Ndagi, Umar
    Mhlongo, Ndumiso N.
    MOLECULAR SIMULATION, 2021, 47 (16) : 1313 - 1325
  • [35] Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis
    He, Xin
    Alian, Akram
    Stroud, Robert
    de Montellano, Paul R. Ortiz
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (21) : 6308 - 6323
  • [36] Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis
    Sink, Roman
    Sosic, Izidor
    Zivec, Matej
    Fernandez-Menendez, Raquel
    Turk, Samo
    Pajk, Stane
    Alvarez-Gomez, Daniel
    Lopez-Roman, Eva Maria
    Gonzales-Cortez, Carolina
    Rullas-Triconado, Joaquin
    Angulo-Barturen, Inigo
    Barros, David
    Ballell-Pages, Lluis
    Young, Robert J.
    Encinas, Lourdes
    Gobec, Stanislav
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (02) : 613 - 624
  • [37] Structural modification of a novel inhibitor for mycobacterium enoyl-acyl carrier protein reductase assisted by In silico structure-based drug screening
    Taira, Junichi
    Nagano, Toshiki
    Kitamura, Mitsuru
    Yamaguchi, Miho
    Sakamoto, Hiroshi
    Aoki, Shunsuke
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2020, 9 (01) : 12 - 17
  • [38] Charge density distribution and electrostatic interactions of ethionamide: an inhibitor of the enoyl acyl carrier protein reductase (inhA) enzyme of Mycobacterium tuberculosis
    Rajalakshmi, G.
    Pavan, Mysore S.
    Kumaradhas, P.
    RSC ADVANCES, 2014, 4 (101) : 57823 - 57833
  • [39] 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study
    Venugopala, Katharigatta N.
    Deb, Pran Kishore
    Pillay, Melendhran
    Chopra, Deepak
    Chandrashekharappa, Sandeep
    Morsy, Mohamed A.
    Aldhubiab, Bandar E.
    Attimarad, Mahesh
    Nair, Anroop B.
    Sreeharsha, Nagaraja
    Kandeel, Mahmoud
    Venugopala, Rashmi
    Mohanlall, Viresh
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2021, 21 (04) : 295 - 306
  • [40] Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles
    Kouassi, Affiba Florance
    Kone, Mawa
    Keita, Melalie
    Esmel, Akori
    Megnassan, Eugene
    N'Guessan, Yao Thomas
    Frecer, Vladimir
    Miertus, Stanislav
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (12) : 29744 - 29771